OTCMKTS:ENZNEnzon Pharmaceuticals Stock Price, Forecast & News

$0.17

0.00 (0.00 %)

(As of 06/3/2020 02:56 PM ET)

Add

Compare

Today's Range

$0.17

Now: $0.17▼

$0.18

50-Day Range

$0.15

MA: $0.17▼

$0.18

52-Week Range

$0.14

Now: $0.17▼

$0.31

Volume12,444 shs

Average Volume18,469 shs

Market Capitalization$7.53 million

P/E Ratio1.25

Dividend YieldN/A

Beta0.16

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. Its marketed drug products include PegIntron for use in the treatment of chronic hepatitis C; and Sylatron for use in the treatment of melanoma disease. The company was founded in 1981 and is headquartered in Cranford, New Jersey.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Enzon Pharmaceuticals.

2.8 Community Rank

Outperform Votes
Enzon Pharmaceuticals has received 107 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Enzon Pharmaceuticals has received 83 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Enzon Pharmaceuticals has received 56.32% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Enzon Pharmaceuticals and other stocks. Vote “Outperform” if you believe ENZN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ENZN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Enzon Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Enzon Pharmaceuticals does not have a long track record of dividend growth.

3.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Enzon Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $104,436.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 0.06% of the stock of Enzon Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 0.02% of the stock of Enzon Pharmaceuticals is held by institutions.

1.3 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Enzon Pharmaceuticals is 1.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 16.08.
Price to Earnings Ratio vs. Sector
The P/E ratio of Enzon Pharmaceuticals is 1.25, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.36.
Price to Book Value per Share Ratio
Enzon Pharmaceuticals has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.41 out of 5 stars

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Biological products, except diagnostic

Sub-IndustryBiotechnology

SectorMedical

Current SymbolOTCMKTS:ENZN

Previous SymbolNASDAQ:ENZN

CUSIP29390410

CIK727510

Webwww.enzon.com

Phone732-980-4500

Debt

Debt-to-Equity RatioN/A

Current Ratio14.71

Quick Ratio14.71

Price-To-Earnings

Trailing P/E Ratio1.25

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$210,000.00

Price / Sales35.84

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.14 per share

Price / Book1.22

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-980,000.00

Net Margins-326.92%

Return on Equity-11.28%

Return on Assets-9.14%

Miscellaneous

EmployeesN/A

Outstanding Shares44,220,000

Market Cap$7.53 million

Next Earnings Date8/5/2020 (Estimated)

OptionableNot Optionable

Receive ENZN News and Ratings via Email

Sign-up to receive the latest news and ratings for ENZN and its competitors with MarketBeat's FREE daily newsletter.

Enzon Pharmaceuticals (OTCMKTS:ENZN) Frequently Asked Questions

How has Enzon Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Enzon Pharmaceuticals' stock was trading at $0.1693 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ENZN stock has increased by 0.5% and is now trading at $0.1702. View which stocks have been most impacted by Coronavirus.

When is Enzon Pharmaceuticals' next earnings date?

Enzon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Enzon Pharmaceuticals.

How were Enzon Pharmaceuticals' earnings last quarter?

Enzon Pharmaceuticals Inc (OTCMKTS:ENZN) released its earnings results on Thursday, April, 30th. The biotechnology company reported ($0.01) earnings per share for the quarter. Enzon Pharmaceuticals had a negative net margin of 326.92% and a negative return on equity of 11.28%. View Enzon Pharmaceuticals' earnings history.

Has Enzon Pharmaceuticals been receiving favorable news coverage?

Media headlines about ENZN stock have been trending somewhat positive on Wednesday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Enzon Pharmaceuticals earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutEnzon Pharmaceuticals.

Who are some of Enzon Pharmaceuticals' key competitors?

Some companies that are related to Enzon Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors.

What other stocks do shareholders of Enzon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enzon Pharmaceuticals investors own include Amplify Energy (AMPY), Amplify Energy (AMPY), AEterna Zentaris (AEZS), CBL & Associates Properties (CBL), NGL Energy Partners (NGL), Pennsylvania R.E.I.T. (PEI), Chesapeake Energy (CHK), Summit Midstream Partners (SMLP), Golar LNG Partners (GMLP) and Washington Prime Group (WPG).

Who are Enzon Pharmaceuticals' key executives?

Enzon Pharmaceuticals' management team includes the following people:

Mr. Andrew Rackear, CEO & Sec. (Age 65)
Mr. Richard L. Feinstein, VP of Fin. & CFO (Age 76)

What is Enzon Pharmaceuticals' stock symbol?

Enzon Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ENZN."

How do I buy shares of Enzon Pharmaceuticals?

Shares of ENZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Enzon Pharmaceuticals' stock price today?

One share of ENZN stock can currently be purchased for approximately $0.17.

How big of a company is Enzon Pharmaceuticals?

Enzon Pharmaceuticals has a market capitalization of $7.53 million and generates $210,000.00 in revenue each year.

What is Enzon Pharmaceuticals' official website?

The official website for Enzon Pharmaceuticals is www.enzon.com.

How can I contact Enzon Pharmaceuticals?

Enzon Pharmaceuticals' mailing address is 20 Commerce Drive Suite 135, Cranford NJ, 07016. The biotechnology company can be reached via phone at 732-980-4500 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff